Apixaban-PK Trial: Preventing Portal Hypertension Complications in Cirrhosis
Recruiting
Phase 4
Interventional Study
Cirrhosis
Esophageal and Gastric Varices
Ascites
Hepatic Encephalopathy
Portal Vein Thrombosis
Portal Hypertension
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Trial phase
- Phase 4
- Study type
- Interventional
- Purpose
- Prevention
- Participants needed
- 220 (estimated)
- Sponsor
- Asian Institute Of Medical Sciences · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The APIXABAN-PK trial is a prospective, randomized, single-blind, placebo-controlled study designed to evaluate the efficacy and safety of apixaban in combination with carvedilol versus placebo with carvedilol in preventing portal hypertension-related complications in patients with cirrhosis. Conducted at the Gastroenterology and Hepatology Department and Clinical Trials Unit (CTU) of Asian Instit…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
1. Adults aged ≥18 years with diagnosed cirrhosis (any etiology), confirmed by histology, transient elastography (≥12.5 kPa), or consistent clinical/imaging findings.
2. Evidence of portal hypertension, defined by:
Clinical: presence of varices on endoscopy, ascites, or sple…
Contacts